Drug intelligence / Profile preview

TB-NOD-2

Development stage: Preclinical
Lead developer: Traverse Biotech
Modality: Small Molecules

Overview

TB-NOD-2 is a small molecule therapeutic candidate developed by Traverse Biotech that acts as an agonist of the Nucleotide-binding oligomerization domain-containing protein 2 (NOD2). By stimulating this cytosolic pattern recognition receptor, the drug aims to activate innate immune signaling pathways, which can enhance anti-tumor immunity in oncology and potentially address neuroinflammatory mechanisms in neurodegenerative diseases. The asset is currently in the early stages of development within Traverse Biotech's pipeline of innate immune modulators.

Targets

NOD2 (Nucleotide-binding oligomerization domain-containing protein 2)

Beyond the preview

Go deeper on TB-NOD-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TB-NOD-2.

Explore the full profile